This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
New Drug Research and Development
Upholding the core value of innovation, we provide better treatment outcomes for patients through scientific innovation, focusing on therapeutic areas including cancer and tumor immunotherapy-related drugs.
Microbial Symbiotic Fermentation Platform
Since 1997, Microbio has been developing a unique microbial symbiotic fermentation technology platform based on the concept of simulating intestinal ecology. This platform is used to research and produce drugs that regulate the balance of intestinal bacterial flora. The human intestine contains over 500 species of bacteria, which colonize different parts of the digestive tract, coordinating and restricting each other to form a balanced ecosystem that plays a crucial role in maintaining human health. In recent years, research on intestinal bacteria has become a focal point in global microbiology, clinical medicine, basic biology, genetics, and metabolomics. Using human intestinal microbiota as a strategy for new drug development has become an international trend. Currently, Microbio possesses the world’s exclusive anaerobic symbiotic fermentation technology for intestinal bacteria, which serves as a fundamental advantage in gut microbiota research. Additionally, Microbio has inherent experience in large-scale factory production, making the expansion of the microbial symbiotic fermentation platform technology a key focus of their research and development.
New Drug Development Platform
The core value of Microbio’s new drug development platform is to bring significant treatment strategies to global patients based on scientific foundations and professional knowledge, dedicated to developing innovative drugs. In 2001, Microbio began its first clinical trial for a new cancer drug. After 12 years of refinement, Microbio has recruited and trained a cancer clinical research and development team composed of domestic and international elites, accumulating rich practical experience in clinical design, project execution, and result analysis. This includes successfully obtaining 2 new drug approvals, 4 U.S. FDA new drug clinical trial approvals, 8 new drug clinical trial approvals, and IRB clinical trial approvals from major medical centers and teaching hospitals in Taiwan. In the future, the focus will be on enhancing new research and development technologies, seeking international cooperation and alignment, and developing new indications.
Specialty Supplements
Health is the foundation for enjoying a good life. Microbio upholds professional and rigorous research and development management, combining a top-notch R&D team with biotechnology R&D technology and GMP pharmaceutical manufacturing process quality control to produce high-quality medical health products. These include patented specialty leading products such as Tianzhongbao, Premium Enzymes, and Li Shizhen Six-Flavor Compound. Microbio is committed to developing specialty health care products, aiming to produce ‘healthy, safe, and effective’ products to provide the best health protection.